Loss of CD55 Is Associated with Aggressive Breast Tumors

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2797-2803

  Madjd, Zahra ^a   Durrant, Lindy G ^a,b   Bradley, Richard ^a   Spendlove, Ian ^a   Ellis, Ian O ^a   Pinder, Sarah E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; ANTIGENS, CD59; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; PEPTIDES; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1942470075     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1073-03     Document Type: Article

References (26)

1. Kinoshita T. Overview of complement biology. Immunol Today 1991;12:291-300.
2. Gal P, Ambrus G. Structure and function of complement activating enzyme complexes: C1 and MBL-MASPs. Curr Protein Pept Sci 2001;2:43-59.
3. Davitz MA. Decay accelerating factor (DAF): a review of its function and structure. Acta Med Scand Suppl 1986;715:111-21.
4. Nicholson-Weller A, Wang C. Structure and function of decay-accelerating factor CD55. J Lab Clin Med 1994;123:485-91.
5. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996;61:201-83.
6. Li L, Spendlove I, Morgan J, Durrant LG. CD55 is overexpressed in the tumour environment. Br J Cancer 2001;84:80-6.
7. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996;149:129-42.
8. Thorsteinsson L, O'Dowd GM, Harrington PM, Johnson PM. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 1998;106:869-78.
9. Hofman P, Hsi BL, Manie S, Fenichel P, Thyss A, Rossi B. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack. Breast Cancer Res Treat 1994;32:213-9.
10. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 2003;52:638-842.
11. Koretz K, Bruderlein S, Henne C, Moller P. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br J Cancer 1992;66:810-4.
12. Koretz K, Bruderlein S, Henne C, Moller P. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 1993;68:926-31.
13. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 2003;200:633-9.
14. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity, 1975. Biotechnology 1992;24:524-626.
15. Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature (Lond.) 1977;266:550-2.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
17. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
18. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type relationship with survival in a large study with long-term follow-up. Histopathology 1992;20:479-89.
19. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV. Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27:219-26.
20. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994;24:41-7.
21. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-19.
22. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF, Blamey RW. The prognosis of small primary breast cancers. Eur J Cancer 1999;35:908-12.
23. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
24. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-21.
25. Harris CL, Lublin DM, Morgan BP. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. J Immunol Methods 2002;268:245-58.
26. Seya T, Hara T, Matsumoto M, Sugita Y, Akedo H. Complement mediated tumour cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J Exp Med 1990;172:1673-80.